Raloxifene at least as effective as tamoxifen study shows

In collaboration with the Press Association

New trial results have shown that raloxifene is at least as effective at cutting the incidence of breast cancer among post-menopausal women as tamoxifen.

Raloxifene was also shown to reduce the risks of side effects compared to tamoxifen.

Both drugs reduce the risk of breast cancer among high risk older women by about half. Neither is yet available as a breast cancer prevention in the UK, however. "These are early results and longer follow-up is needed to observe its impact on long-term prevention as well as the overall benefits of the drug," said professor John Toy, medical director of Cancer Research UK.

"Cancer Research UK is researching preventive options for women at high-risk of breast cancer.

"The IBIS-2 trial is investigating whether a drug called anastrozole could be even more effective than tamoxifen at preventing breast cancer, with acceptable side effects.

"This international trial is recruiting women in the UK who have been through the menopause and think they may be at high-risk of breast cancer," he added.

Breast cancer is the most common cancer among women in the UK, with 42,000 new cases diagnosed every year.

Visit the IBIS-2 website

Read more about breast cancer treatment on our patient information website, CancerHelp UK